Cardiac Rehabilitation Market To Reach USD 2.29 Billion By 2026 | Reports and Data
March 02, 2020 14:00 ET
|
Reports and Data
New York, March 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the cardiac rehabilitation market was valued at USD 1.37 billion in 2018 and is expected to reach...
Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
November 10, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
October 25, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
June 15, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
January 08, 2015 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Non-Emergency Angioplasty Costs Higher in Hospitals Without Back-Up Surgery
November 04, 2012 20:52 ET
|
American Heart Association
Study highlights:
Angioplasty costs for treating patients with stable symptoms are slightly higher in hospitals that do not have emergency heart surgery back-up, compared to those that do,...
Multiple Factors Influence Five-Year Survival After Angioplasty, Bypass Procedures
May 11, 2012 09:00 ET
|
American Heart Association
FRIDAY NEWS TIP
Embargoed for 9 a.m. ET
ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) --The effectiveness of heart bypass grafts and angioplasty procedures on five-year survival varies significantly...
Two Anti-Clotting Regimens Similarly Effective in Patients Undergoing Angioplasty After Heart Attack
November 13, 2011 08:00 ET
|
American Heart Association
Study Highlights:
Two anti-clotting treatments ― abciximab with heparin, or bivalirudin ― were similar in preventing death, subsequent heart attack or need for further...
Emergency Treatment for Heart Attack Improving but Delays Still Occur
September 19, 2011 16:00 ET
|
American Heart Association
Study highlights:
Although improvements have been made in emergency heart attack treatment, delays still occur, particularly in transferring patients to hospitals that perform artery-opening...